Your browser doesn't support javascript.
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.
Terpos, Evangelos; Trougakos, Ioannis P; Karalis, Vangelis; Ntanasis-Stathopoulos, Ioannis; Gumeni, Sentiljana; Apostolakou, Filia; Sklirou, Aimilia D; Gavriatopoulou, Maria; Skourti, Stamatia; Kastritis, Efstathios; Korompoki, Eleni; Papassotiriou, Ioannis; Dimopoulos, Meletios A.
  • Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Trougakos IP; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Karalis V; Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Gumeni S; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Apostolakou F; Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.
  • Sklirou AD; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Gavriatopoulou M; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Skourti S; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Kastritis E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Korompoki E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Papassotiriou I; Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.
  • Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Cells ; 10(8)2021 07 30.
Article in English | MEDLINE | ID: covidwho-1335013
ABSTRACT
The aim of this study was to investigate the kinetics of neutralizing antibodies (NAbs) and anti-SARS-CoV-2 anti-S-RBD IgGs up to three months after the second vaccination dose with the BNT162b2 mRNA vaccine. NAbs and anti-S-RBD levels were measured on days 1 (before the first vaccine shot), 8, 22 (before the second shot), 36, 50, and three months after the second vaccination (D111) (NCT04743388). 283 health workers were included in this study. NAbs showed a rapid increase from D8 to D36 at a constant rate of about 3% per day and reached a median (SD) of 97.2% (4.7) at D36. From D36 to D50, a slight decrease in NAbs values was detected and it became more prominent between D50 and D111 when the rate of decline was determined at -0.11 per day. The median (SD) NAbs value at D111 was 92.7% (11.8). A similar pattern was also observed for anti-S-RBD antibodies. Anti-S-RBDs showed a steeper increase during D22-D36 and a lower decline rate during D36-D111. Prior COVID-19 infection and younger age were associated with superior antibody responses over time. In conclusion, we found a persistent but declining anti-SARS-CoV-2 humoral immunity at 3 months following full vaccination with BNT162b2 in healthy individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Risk factors Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Year: 2021 Document Type: Article Affiliation country: Cells10081942

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Observational study / Risk factors Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Year: 2021 Document Type: Article Affiliation country: Cells10081942